The role of allogeneic hematopoietic stem cell transplantation in adults with mature T-cell lymphomas.
Laura Diana Stocker, Lisa Thielecke, Constantin Schmitz et al.
✦ AI-curated · Sources linked
In 30 seconds
This Cochrane systematic review and meta-analysis assessed allogeneic stem cell transplantation (alloSCT) for adults with mature T-cell lymphomas (MTCL), as first-line or salvage treatment. It included one randomised trial comparing first-line alloSCT with autologous transplantation (103 participants) and two prospectively planned salvage studies (119 participants). Evidence was low to very low certainty, and the studies were too few for meta-analysis. In the first-line trial, alloSCT may make little or no difference to two-year overall survival (HR 1.3, 95% CI 0.7 to 2.4) or progression-free survival (HR 0.9, 95% CI 0.5 to 1.5), but may increase treatment-related mortality (RR 18.70, 95% CI 1.11 to 315.72).
Key findings
- First-line alloSCT versus autologous transplantation may make little or no difference to two-year overall survival (HR 1.3, 95% CI 0.7 to 2.4).
- Progression-free survival may be similar with first-line alloSCT and autologous transplantation (HR 0.9, 95% CI 0.5 to 1.5).
- First-line alloSCT may increase treatment-related mortality (RR 18.70, 95% CI 1.11 to 315.72), although the estimate is imprecise.
- The review included two prospectively planned salvage studies, but the abstract reports no quantitative salvage-treatment results.
Why it matters
MTCL has a generally poor prognosis, and transplantation is considered as a way to improve outcomes. This review indicates that, in the available first-line comparison, a survival advantage for alloSCT over autologous transplantation is not established, while treatment-related mortality may be higher. The findings help frame the potential trade-off, but substantial uncertainty limits conclusions about benefits and harms.
What to keep in mind
Evidence was low to very low certainty because of few studies and events and limitations in study design. The first-line comparison came from one trial; the salvage evidence included a small prospective observational study. No meta-analysis was possible.